Skip to Main Content

Paper Details

Effects of canagliflozin on liver steatosis and fibrosis markers in patients with type 2 diabetes and chronic kidney disease: A post hoc analysis of the CREDENCE trial.
Diabetes Obes Metab
1
2023
Author NameAffiliation
Kenneth W MahaffeyStanford Center for Clinical Research, Stanford University School of Medicine
  • 1 - 1

Datasets

Release 1.2